BioMark Diagnostics, Inc. · CSE:BUX
BioMark Diagnostics — Investor Presentation (July 2015)
25 slides from BioMark Diagnostics's investor presentation, July 2015

Slide 1: BioMark Diagnostics: A Next Generation Company Powered by Metabolomics
BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics

Slide 2: Why We Are / Who We Are
BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics WHY WE ARE • To empower people, medical institutions and nations to gain universal access to effective cancer diagnostic tools. • To accelerate and facilitate wellness from labs to villages. WHO WE ARE • BioMark is an oncology

Slide 3: Proven Science
Proven Science • BioMark Diagnostics Inc. has developed and in the process of marketing cutting edge diagnostics for the ultra-early detection of carcinomas. • BioMark has developed a frontline pan-cancer detection system based on the over-expression of an enzyme found in carcinomas. This enzyme is

Slide 4: SSAT1-Amantadine Assay
SSAT1-Amantadine Assay • SSAT1 is a key enzyme in the polyamine pathway that converts spermine and spermidine into their acetylated forms. • Elevated levels of SSAT1 has been reported in numerous cancers. • SSAT1 has a high affinity for Amantadine and readily converts it into N- acetylamantadine. (f

Slide 5: SSAT1-Amantadine Assay
SSAT1-Amantadine Assay Amantadine is the preferred substrate for SSAT (activity of SSAT to substrate) Pancreatic Cancer Cells Normal Pancreatic Cells BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics

Slide 6: SSAT1-Amantadine Assay Benefits
SSAT1-Amantadine Assay Benefits • Non-invasive. • Cost effective. • Highly accurate. • When detected early, over 90% of cancers can be cured. • True promise of improved patient prognosis. BioMark DIAGNOSTICS INC A Next Generation Company Powered by Metabolomics

Slide 7: Methods of N-acetylamantadine Detection
Methods of N-acetylamantadine Detection • Liquid Chromatography with tandem Mass Spectrometry • Highly accurate detection of N-acetylamantadine in urine samples with little error in measurement. • Limited to laboratories and clinical settings. • Developed internal standard • ELISA Kit • Highly accur

Slide 8: SSAT1 Expression Signatures Diagnostic Assay
SSAT1 Expression Signatures Diagnostic Assay • By measuring the levels of SSAT1 in cancer versus healthy cells, BioMark has begun to resolve unique signatures for cancers. • The signatures can be used for secondary follow up assays to the original SSAT1-Amantadine assay. • This approach is slightly

Slide 9: SSAT1 Expression Signatures
SSAT1 Expression Signatures SSAT1 Breast Cancer – Various Grades and Stages • SSAT1 levels vary in different types and stages of cancer. • These levels are consistent in populations within different types and stages of cancer. • BioMark has begun to resolve the SSAT1 expression signatures for breast

Slide 10: Metabolite Fingerprint Diagnostic Assays
Metabolite Fingerprint Diagnostic Assays • By measuring the levels of the various empirically-chosen metabolites associated with cancers, BioMark has begun to resolve unique fingerprints for lung cancer, the most prevalent and deadly cancer. • BioMark plans to resolve fingerprints for the stages of

Slide 11: Metabolite Fingerprints
Metabolite Fingerprints • The levels of metabolite in cancers differ between carcinomas. • These levels are consistent in populations within different types and stages of carcinoma. • BioMark has begun to resolve the fingerprints for lung cancer and its various stages. BioMark DIAGNOSTICS INC A Next

Slide 12: Product and Development Pipeline
Product and Development Pipeline Up to 6 months Planning Development Validation US Approval Market Data points collected and validated SSAT-amantadine Assay using LC MS Transferable to FDA** In collaboration with SSAT-amantadine Assay using ELISA Kestrel Sciences to begin validation Developing N-ace

Slide 13: Transferable Clinical Trials Data
**Transferable Clinical Trials Data • Trials registered at trials.gov • Protocols developed under Health Canada guidelines and approved by both Canadian and Bangladesh ethics boards. • Completed 200 patient screening trial - Lung, Breast and GI Cancer. • Obtained extension of study from Health Canad

Slide 14: Corporate Overview
Corporate Overview • BioMark Diagnostics Inc. is a publicly traded company (CSE:BUX, FSE:20B, OTCQB:BMKDF) located in Vancouver, British Columbia, Canada and is in transition to locate its Global Head Office to Maryland USA. • BioMark was incorporated on June 19, 2014 under the Business Corporation

Slide 15: Capital Structure
Capital Structure BioMark Diagnostics Inc. Quarterly Report December 31, 2014 A. Authorized: Unlimited common shares without par value B. Common Shares Issued: Number Amount Balance, December 31, 2014 47,335,040 $ 1,801,060 Balance, March 2, 2015 48,835,040 $ 2,406,812 As of March 31, 2015 and Decem

Slide 16: Investment Highlights
Investment Highlights Technology Summary & Status 2015 Drivers Utilizes a known FDA-approved drug to act as an Global cancer diagnostic market set to grow to indicator and serve as a biomarker for cancer US $5.3 billion/year detection Industry focus is on early detection and Patent issued in 2004 wi

Slide 17: Target Market Focus
Target Market Focus Market Focus Market Potential Lung Cancer: Response to Treatment Screening + Companion Diagnostics = $2.2 Billion Red Alert for Cancer Recurrence North America: 15 Million Cancer Survivors General Cancer Screening Globally: Over 4 Billion Patients Big Data and Analytics Early rev

Slide 18: Global Cancer Diagnostic Market
Global Cancer Diagnostic Market Next Generation Cancer Diagnostic Market Growth Projections Size of Next Generation Cancer Diagnostic 12 to Total Diagnostic Market 2014 - 2019 10 Dollars in Billions USD 8 $117.6 $157.5 Billion Billion 42.6% $10 B 6 CAGR 10 B $1.8 B 4 2014 2019 2 1.8 B 0 2014 2019 Ye

Slide 19: BioMark Market Share Outlook
BioMark Market Share Outlook BioMark’s Projected Size of Next Generation Diagnostics Market • BioMark’s goal in the next 24 months is to capture a 2%-5% market share of the next generation cancer Dollars in Millions USD diagnostics sector representing an immediate $36 million to $90 million market o

Slide 20: Model to Market - How to Capture Share
Model to Market - How to Capture Share Focus on • Medical Lab providers - LabCorp, DirectLabs, Quest Diagnostics and WellnessFx Healthcare has been shifting from curative care to detection, prevention and personalized care over the past five years, which has benefited the Diagnostic and Medical Labo

Slide 21: Multiple Revenue Generating Streams Contributing to Growth
Multiple Revenue Generating Streams Contributing to Growth Sales Royalty Product / Supplies • Lab analysis per test • Package with certified pills Licensing • Certified internal standard supply • Territorial and distribution licensing (DA) for authorized labs Services • Elisa and Kits for point of c

Slide 22: Multiple Revenue Generating Streams Contributing to Growth
Multiple Revenue Generating Streams Contributing to Growth • Increased Manufacturing • Collected by of SERS, ELISA physician. & IVD capabilities. Urine Sample Customized Package Collection Sequoia Seedlings Big things start with foundation Physician Report and Data Base Lab Analysis Collection • Cas

Slide 23: Executive Team
Executive Team Rashid Ahmed - Founder, Chief Executive Officer Dr. Thomas Malcolm - President & Chief Scientific Officer Brian Cheng - Chief Technical Officer Abbey Abdiye - Chief Financial Officer (Canada) Neal Kaplan - Chief Financial Officer (US) Dr. Kenneth Kohn - Patent Attorney Gina Huang - Pr

Slide 24: Scientific & Supporting Board
Scientific & Supporting Board Dr. Daniel S. Sitar - Principal Scientific Advisor/Consultant Dr. Thomas Malcolm - Chief Scientific Officer Dr. Kenneth Kohn - Patent Attorney Dr. John Yoo - Clinical Oncologist - Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of

Slide 25: Summary
Summary • BioMark has innovated a new paradigm for Next Generation cancer diagnostics. • BioMark’s comprehensive metabolomics approach to detecting early cancer is unparalleled. • BioMark’s technology is disruptive in the industry and will set new standards in the years to come. • BioMark has multip
Source: Internet Archive copy of biomarkdiagnostics.com
More decks from BioMark Diagnostics, Inc.
Investor Presentation (September 2025)23 slides · September 2025
Investor Presentation (April 2023)42 slides · April 2023
Investor Presentation (July 2022)33 slides · July 2022
Investor Presentation (May 2021)26 slides · May 2021
Investor Presentation (June 2019)32 slides · June 2019
Investor Presentation (June 2016)23 slides · June 2016